Validation of a Transfusion Prediction Model in Head and Neck Cancer Surgery

Krupp, Nadia; Weinstein, Gregory S.; Chalian, Ara A.; Berlin, Jesse A.; Wolf, Pat; Weber, Randal S.

doi:10.1001/archotol.129.12.1297

Cited by 39 publications

(51 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is to be expected in such analyses when the original model is applied to a new sample of patients from another institution in a separate country. However, a model with an area under the ROC curve of 0.74 (95% CI: 0.66-0.82) tested in an external sample of patients is still considered to provide reasonable predictive accuracy [17]. Nevertheless, clinicians who use our risk model should be aware that some loss of accuracy will occur when applied to new patients.…”

Section: Discussionmentioning

confidence: 99%

“…Discrimination refers to the ability of a diagnostic test or predictive tool to accurately identify patients at low and high risk for the event under investigation and is often presented as the area under the ROC curve. A predictive instrument with a ROC of ≥0.70 is considered to have good discrimination, and an area of 0.5 is equivalent to a "coin toss" [17]. In the current study, two sets of validation were performed with an internal and external sample.…”

Section: Validation Of Prediction Modelmentioning

confidence: 99%

See 1 more Smart Citation

The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy

Vincent¹,

Dranitsaris

Verma

et al. 2006

Support Care Cancer

View full text Add to dashboard Cite

We developed and validated an anemia prediction tool for advanced stage NSCLC patients receiving palliative chemotherapy. To make the model available for easy use and access, we have incorporated it on to our risk prediction website: http://www.PredictPatientEvents.com . It is hoped that this risk model will enhance patient care by optimizing the frequency of Hb testing and/or the use of preventative therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Validation Of Prediction Modelmentioning

confidence: 99%

The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy

Vincent¹,

Dranitsaris

Verma

et al. 2006

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…According to the literature, blood transfusion is required in 14-80% of all head and neck cancer operations [8]. However, within our unit only 16% of major head and neck operations required blood transfusion (11 of 68 cases transfused between August 2008-August 2009).…”

Section: Discussionmentioning

confidence: 98%

Case report: The management of advanced oral cancer in a Jehovah's Witness using the Ultracision Harmonic Scalpel

et al. 2011

View full text Add to dashboard Cite

We present the first case of a head and neck oncological procedure accomplished in a Jehovah's Witness using the Ultracision Harmonic Scalpel (Ethicon, Cincinnati, OH). Jehovah's Witnesses present a serious challenge to the head and neck cancer surgeon due to their refusal to accept transfusion of any blood products. However, our experience reinforces the view that surgical management of head and neck cancer is possible in these patients. We show the Harmonic Scalpel, an ultrasonic tissue dissector, to be a useful surgical tool in obviating the need for blood transfusion. Preoperative optimisation, intra-operative surgical and anaesthetic techniques are also fully discussed.

show abstract

“…The time-independent ROC curve was employed to evaluate the discrimination of the risk model and the FIGO stage system, which was performed by R software. As described by previous studies, the model is considered to have good discrimination if the area under the ROC curve (AUC) is greater than 0.753435. All p -values were two-tailed, and values < 0.05 were considered statistically significant.…”

Section: Methodsmentioning

confidence: 99%

Prognostic risk model development and prospective validation among patients with cervical cancer stage IB2 to IIB submitted to neoadjuvant chemotherapy

Huang

Sun

Xiong

et al. 2016

Sci Rep

View full text Add to dashboard Cite

This study was designed to develop a risk model for disease recurrence among cervical cancer patients who underwent neoadjuvant chemotherapy and radical surgery. Data for 853 patients were obtained from a retrospective study and used to train the model, and then data for 447 patients from a prospective cohort study were employed to validate the model. The Cox regression model was used for calculating the coefficients of the risk factors. According to risk scores, patients were classified into high-, intermediate-, and low-risk groups. There were 49 (49/144, 34%) recurrences observed in the high-risk group (with a risk score ≥ 2.65), compared with 3 (3/142, 2%) recurrences in the low-risk group (with a risk score < 0.90). Disease-free survival (DFS) was significantly different (log-rank p < 0.001) among the three risk groups; the risk model also revealed a significant increase in the accuracy of predicting 5-year DFS with the area under the ROC curve (AUC = 0.754 for risk model vs 0.679 for FIGO stage system); the risk model was also validated with data from the prospective study (log-rank p < 0.001, AUC = 0.766). Both high-risk and intermediate-risk patients can be more effectively identified by this risk model.

show abstract

Validation of a Transfusion Prediction Model in Head and Neck Cancer Surgery

Cited by 39 publications

References 9 publications

The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy

The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy

Case report: The management of advanced oral cancer in a Jehovah's Witness using the Ultracision Harmonic Scalpel

Prognostic risk model development and prospective validation among patients with cervical cancer stage IB2 to IIB submitted to neoadjuvant chemotherapy

Contact Info

Product

Resources

About